Global Cytomegalovirus Infection Market

Cytomegalovirus Infection Comprehensive Study by Type (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir), Application (Hospitals, Retail Pharmacies, Online Pharmacies), Infection (Retinitis, Pneumonia, Gastroenteritis, Others (Mouth ulcers, Pharyngitis)), Test type (Serology, Cell culture, Antigenemia, Polymerase Chain Amplification, Immunohistochemistry, Nucleic acid sequence-based amplification (NASBA), Hybrid Capture assay), Drug class (Antiviral drugs, Foscarnet, Cytovene, Vistide, Others) Players and Region - Global Market Outlook to 2028

Cytomegalovirus Infection Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to the Center for Disease Control and Prevention (CDC), in the United States, each year around 150 infants are born with cytomegalovirus infections and few of them have long term health problems. Cytomegalovirus (CMV) infection is the common herpes virus infection which has different symptoms that occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and spread through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease. The infection can be diagnosed through serological testing methods such as Enzyme-linked immunoassay test.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledF. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AiCuris Anti-infective Cures GmbH (Germany), Vical, Inc. (United States), Chimerix, Inc. (United States), ViroPharma (United States), Roche Holding AG (Switzerland), Clinigen Group Plc (United Kingdom), CSL Behring (United States), GlaxoSmithKline (United Kingdom), Gilead Sciences (United States), Merck & Co. (United States), Biotest AG (Germany), Shire Pharmaceuticals (United States), Atara Biotherapeutics (United States) and Helocyte, Inc. (United States)


This growth is primarily driven by Increase in the prevalence of CMV infections globally, Rising awareness associated with rare diseases like CMV, Developing healthcare infrastructure and high disposable income and High investment of the Government for the Research & Development (R&D) of novel therapies and drugs to treat CMV infections..

Globally, a noticeable market trend is evident The immense pace of R&D activities due to the presence of large biotechnology and pharmaceutical companies. The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AiCuris Anti-infective Cures GmbH (Germany), Vical, Inc. (United States), Chimerix, Inc. (United States), ViroPharma (United States), Roche Holding AG (Switzerland), Clinigen Group Plc (United Kingdom), CSL Behring (United States), GlaxoSmithKline (United Kingdom), Gilead Sciences (United States), Merck & Co. (United States), Biotest AG (Germany), Shire Pharmaceuticals (United States), Atara Biotherapeutics (United States) and Helocyte, Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market appears to be fragmented due to a large number of players in the market who are heavily investing in R&D for the development of novel therapies and drugs to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are paying more attention on novel drugs by giving faster approvals and special status for the drugs.

Key Developments in the Market:
On September 21, 2023, Vir Biotechnology, a leading immunology company, and GlaxoSmithKline (GSK), a global pharmaceutical company, announced a strategic collaboration to develop and commercialize novel therapies for CMV infection.
On October 4, 2023, Argenx, a clinical-stage biopharmaceutical company focused on developing antibody-based therapies, announced a collaboration agreement with Atomwise, an AI-powered drug discovery company, to identify and develop novel therapies for CMV infection.

Influencing Trend:
The immense pace of R&D activities due to the presence of large biotechnology and pharmaceutical companies.

Market Growth Drivers:
Increase in the prevalence of CMV infections globally, Rising awareness associated with rare diseases like CMV, Developing healthcare infrastructure and high disposable income and High investment of the Government for the Research & Development (R&D) of novel therapies and drugs to treat CMV infections.

Challenges:
Vaccine development for CMV infection, where the number of vaccines candidates are still under investigation and Cost factor associated with the treatment of CMV infection is posing a challenge for the market.

Restraints:
Lack of awareness about CMV infection in developing and underdeveloped countries and price sensitivity and Recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir, Foscarnet are anticipated to hamper the growth of the market.

Opportunities:
Technological advancement in the diagnosis of CMV infection leading to patented drugs for treatment is providing an opportunity for the market.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Cytomegalovirus Infection Market
- Analysis about New Entrants in Cytomegalovirus Infection Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Cytomegalovirus Infection Study Sheds Light on
— The Cytomegalovirus Infection Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cytomegalovirus Infection industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cytomegalovirus Infection industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Cidofovir
  • Foscarnet
  • Valganciclovir
  • Ganciclovir
By Application
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
By Infection
  • Retinitis
  • Pneumonia
  • Gastroenteritis
  • Others (Mouth ulcers, Pharyngitis)

By Test type
  • Serology
  • Cell culture
  • Antigenemia
  • Polymerase Chain Amplification
  • Immunohistochemistry
  • Nucleic acid sequence-based amplification (NASBA)
  • Hybrid Capture assay

By Drug class
  • Antiviral drugs
  • Foscarnet
  • Cytovene
  • Vistide
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the prevalence of CMV infections globally
      • 3.2.2. Rising awareness associated with rare diseases like CMV
      • 3.2.3. Developing healthcare infrastructure and high disposable income
      • 3.2.4. High investment of the Government for the Research & Development (R&D) of novel therapies and drugs to treat CMV infections.
    • 3.3. Market Challenges
      • 3.3.1. Vaccine development for CMV infection, where the number of vaccines candidates are still under investigation
      • 3.3.2. Cost factor associated with the treatment of CMV infection is posing a challenge for the market.
    • 3.4. Market Trends
      • 3.4.1. The immense pace of R&D activities due to the presence of large biotechnology and pharmaceutical companies.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cytomegalovirus Infection, by Type, Application, Infection, Test type, Drug class and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cytomegalovirus Infection (Value)
      • 5.2.1. Global Cytomegalovirus Infection by: Type (Value)
        • 5.2.1.1. Cidofovir
        • 5.2.1.2. Foscarnet
        • 5.2.1.3. Valganciclovir
        • 5.2.1.4. Ganciclovir
      • 5.2.2. Global Cytomegalovirus Infection by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Cytomegalovirus Infection by: Infection (Value)
        • 5.2.3.1. Retinitis
        • 5.2.3.2. Pneumonia
        • 5.2.3.3. Gastroenteritis
        • 5.2.3.4. Others (Mouth ulcers, Pharyngitis)
      • 5.2.4. Global Cytomegalovirus Infection by: Test type (Value)
        • 5.2.4.1. Serology
        • 5.2.4.2. Cell culture
        • 5.2.4.3. Antigenemia
        • 5.2.4.4. Polymerase Chain Amplification
        • 5.2.4.5. Immunohistochemistry
        • 5.2.4.6. Nucleic acid sequence-based amplification (NASBA)
        • 5.2.4.7. Hybrid Capture assay
      • 5.2.5. Global Cytomegalovirus Infection by: Drug class (Value)
        • 5.2.5.1. Antiviral drugs
        • 5.2.5.2. Foscarnet
        • 5.2.5.3. Cytovene
        • 5.2.5.4. Vistide
        • 5.2.5.5. Others
      • 5.2.6. Global Cytomegalovirus Infection Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Cytomegalovirus Infection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AiCuris Anti-infective Cures GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chimerix, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ViroPharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Holding AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Clinigen Group Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CSL Behring (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GlaxoSmithKline (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Gilead Sciences (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Merck & Co. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Biotest AG (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Shire Pharmaceuticals (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Atara Biotherapeutics (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Helocyte, Inc. (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Cytomegalovirus Infection Sale, by Type, Application, Infection, Test type, Drug class and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cytomegalovirus Infection (Value)
      • 7.2.1. Global Cytomegalovirus Infection by: Type (Value)
        • 7.2.1.1. Cidofovir
        • 7.2.1.2. Foscarnet
        • 7.2.1.3. Valganciclovir
        • 7.2.1.4. Ganciclovir
      • 7.2.2. Global Cytomegalovirus Infection by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Cytomegalovirus Infection by: Infection (Value)
        • 7.2.3.1. Retinitis
        • 7.2.3.2. Pneumonia
        • 7.2.3.3. Gastroenteritis
        • 7.2.3.4. Others (Mouth ulcers, Pharyngitis)
      • 7.2.4. Global Cytomegalovirus Infection by: Test type (Value)
        • 7.2.4.1. Serology
        • 7.2.4.2. Cell culture
        • 7.2.4.3. Antigenemia
        • 7.2.4.4. Polymerase Chain Amplification
        • 7.2.4.5. Immunohistochemistry
        • 7.2.4.6. Nucleic acid sequence-based amplification (NASBA)
        • 7.2.4.7. Hybrid Capture assay
      • 7.2.5. Global Cytomegalovirus Infection by: Drug class (Value)
        • 7.2.5.1. Antiviral drugs
        • 7.2.5.2. Foscarnet
        • 7.2.5.3. Cytovene
        • 7.2.5.4. Vistide
        • 7.2.5.5. Others
      • 7.2.6. Global Cytomegalovirus Infection Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cytomegalovirus Infection: by Type(USD Million)
  • Table 2. Cytomegalovirus Infection Cidofovir , by Region USD Million (2017-2022)
  • Table 3. Cytomegalovirus Infection Foscarnet , by Region USD Million (2017-2022)
  • Table 4. Cytomegalovirus Infection Valganciclovir , by Region USD Million (2017-2022)
  • Table 5. Cytomegalovirus Infection Ganciclovir , by Region USD Million (2017-2022)
  • Table 6. Cytomegalovirus Infection: by Application(USD Million)
  • Table 7. Cytomegalovirus Infection Hospitals , by Region USD Million (2017-2022)
  • Table 8. Cytomegalovirus Infection Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 9. Cytomegalovirus Infection Online Pharmacies , by Region USD Million (2017-2022)
  • Table 10. Cytomegalovirus Infection: by Infection(USD Million)
  • Table 11. Cytomegalovirus Infection Retinitis , by Region USD Million (2017-2022)
  • Table 12. Cytomegalovirus Infection Pneumonia , by Region USD Million (2017-2022)
  • Table 13. Cytomegalovirus Infection Gastroenteritis , by Region USD Million (2017-2022)
  • Table 14. Cytomegalovirus Infection Others (Mouth ulcers, Pharyngitis) , by Region USD Million (2017-2022)
  • Table 15. Cytomegalovirus Infection: by Test type(USD Million)
  • Table 16. Cytomegalovirus Infection Serology , by Region USD Million (2017-2022)
  • Table 17. Cytomegalovirus Infection Cell culture , by Region USD Million (2017-2022)
  • Table 18. Cytomegalovirus Infection Antigenemia , by Region USD Million (2017-2022)
  • Table 19. Cytomegalovirus Infection Polymerase Chain Amplification , by Region USD Million (2017-2022)
  • Table 20. Cytomegalovirus Infection Immunohistochemistry , by Region USD Million (2017-2022)
  • Table 21. Cytomegalovirus Infection Nucleic acid sequence-based amplification (NASBA) , by Region USD Million (2017-2022)
  • Table 22. Cytomegalovirus Infection Hybrid Capture assay , by Region USD Million (2017-2022)
  • Table 23. Cytomegalovirus Infection: by Drug class(USD Million)
  • Table 24. Cytomegalovirus Infection Antiviral drugs , by Region USD Million (2017-2022)
  • Table 25. Cytomegalovirus Infection Foscarnet , by Region USD Million (2017-2022)
  • Table 26. Cytomegalovirus Infection Cytovene , by Region USD Million (2017-2022)
  • Table 27. Cytomegalovirus Infection Vistide , by Region USD Million (2017-2022)
  • Table 28. Cytomegalovirus Infection Others , by Region USD Million (2017-2022)
  • Table 29. South America Cytomegalovirus Infection, by Country USD Million (2017-2022)
  • Table 30. South America Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 31. South America Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 32. South America Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 33. South America Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 34. South America Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 35. Brazil Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 36. Brazil Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 37. Brazil Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 38. Brazil Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 39. Brazil Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 40. Argentina Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 41. Argentina Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 42. Argentina Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 43. Argentina Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 44. Argentina Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 45. Rest of South America Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 46. Rest of South America Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 47. Rest of South America Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 48. Rest of South America Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 49. Rest of South America Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 50. Asia Pacific Cytomegalovirus Infection, by Country USD Million (2017-2022)
  • Table 51. Asia Pacific Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 52. Asia Pacific Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 53. Asia Pacific Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 54. Asia Pacific Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 55. Asia Pacific Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 56. China Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 57. China Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 58. China Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 59. China Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 60. China Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 61. Japan Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 62. Japan Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 63. Japan Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 64. Japan Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 65. Japan Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 66. India Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 67. India Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 68. India Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 69. India Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 70. India Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 71. South Korea Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 72. South Korea Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 73. South Korea Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 74. South Korea Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 75. South Korea Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 76. Taiwan Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 77. Taiwan Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 78. Taiwan Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 79. Taiwan Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 80. Taiwan Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 81. Australia Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 82. Australia Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 83. Australia Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 84. Australia Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 85. Australia Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 90. Rest of Asia-Pacific Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 91. Europe Cytomegalovirus Infection, by Country USD Million (2017-2022)
  • Table 92. Europe Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 93. Europe Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 94. Europe Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 95. Europe Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 96. Europe Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 97. Germany Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 98. Germany Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 99. Germany Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 100. Germany Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 101. Germany Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 102. France Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 103. France Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 104. France Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 105. France Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 106. France Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 107. Italy Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 108. Italy Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 109. Italy Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 110. Italy Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 111. Italy Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 112. United Kingdom Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 113. United Kingdom Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 114. United Kingdom Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 115. United Kingdom Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 116. United Kingdom Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 117. Netherlands Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 118. Netherlands Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 119. Netherlands Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 120. Netherlands Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 121. Netherlands Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 122. Rest of Europe Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 123. Rest of Europe Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 124. Rest of Europe Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 125. Rest of Europe Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 126. Rest of Europe Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 127. MEA Cytomegalovirus Infection, by Country USD Million (2017-2022)
  • Table 128. MEA Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 129. MEA Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 130. MEA Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 131. MEA Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 132. MEA Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 133. Middle East Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 134. Middle East Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 135. Middle East Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 136. Middle East Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 137. Middle East Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 138. Africa Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 139. Africa Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 140. Africa Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 141. Africa Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 142. Africa Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 143. North America Cytomegalovirus Infection, by Country USD Million (2017-2022)
  • Table 144. North America Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 145. North America Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 146. North America Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 147. North America Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 148. North America Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 149. United States Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 150. United States Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 151. United States Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 152. United States Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 153. United States Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 154. Canada Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 155. Canada Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 156. Canada Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 157. Canada Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 158. Canada Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 159. Mexico Cytomegalovirus Infection, by Type USD Million (2017-2022)
  • Table 160. Mexico Cytomegalovirus Infection, by Application USD Million (2017-2022)
  • Table 161. Mexico Cytomegalovirus Infection, by Infection USD Million (2017-2022)
  • Table 162. Mexico Cytomegalovirus Infection, by Test type USD Million (2017-2022)
  • Table 163. Mexico Cytomegalovirus Infection, by Drug class USD Million (2017-2022)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Cytomegalovirus Infection: by Type(USD Million)
  • Table 182. Cytomegalovirus Infection Cidofovir , by Region USD Million (2023-2028)
  • Table 183. Cytomegalovirus Infection Foscarnet , by Region USD Million (2023-2028)
  • Table 184. Cytomegalovirus Infection Valganciclovir , by Region USD Million (2023-2028)
  • Table 185. Cytomegalovirus Infection Ganciclovir , by Region USD Million (2023-2028)
  • Table 186. Cytomegalovirus Infection: by Application(USD Million)
  • Table 187. Cytomegalovirus Infection Hospitals , by Region USD Million (2023-2028)
  • Table 188. Cytomegalovirus Infection Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 189. Cytomegalovirus Infection Online Pharmacies , by Region USD Million (2023-2028)
  • Table 190. Cytomegalovirus Infection: by Infection(USD Million)
  • Table 191. Cytomegalovirus Infection Retinitis , by Region USD Million (2023-2028)
  • Table 192. Cytomegalovirus Infection Pneumonia , by Region USD Million (2023-2028)
  • Table 193. Cytomegalovirus Infection Gastroenteritis , by Region USD Million (2023-2028)
  • Table 194. Cytomegalovirus Infection Others (Mouth ulcers, Pharyngitis) , by Region USD Million (2023-2028)
  • Table 195. Cytomegalovirus Infection: by Test type(USD Million)
  • Table 196. Cytomegalovirus Infection Serology , by Region USD Million (2023-2028)
  • Table 197. Cytomegalovirus Infection Cell culture , by Region USD Million (2023-2028)
  • Table 198. Cytomegalovirus Infection Antigenemia , by Region USD Million (2023-2028)
  • Table 199. Cytomegalovirus Infection Polymerase Chain Amplification , by Region USD Million (2023-2028)
  • Table 200. Cytomegalovirus Infection Immunohistochemistry , by Region USD Million (2023-2028)
  • Table 201. Cytomegalovirus Infection Nucleic acid sequence-based amplification (NASBA) , by Region USD Million (2023-2028)
  • Table 202. Cytomegalovirus Infection Hybrid Capture assay , by Region USD Million (2023-2028)
  • Table 203. Cytomegalovirus Infection: by Drug class(USD Million)
  • Table 204. Cytomegalovirus Infection Antiviral drugs , by Region USD Million (2023-2028)
  • Table 205. Cytomegalovirus Infection Foscarnet , by Region USD Million (2023-2028)
  • Table 206. Cytomegalovirus Infection Cytovene , by Region USD Million (2023-2028)
  • Table 207. Cytomegalovirus Infection Vistide , by Region USD Million (2023-2028)
  • Table 208. Cytomegalovirus Infection Others , by Region USD Million (2023-2028)
  • Table 209. South America Cytomegalovirus Infection, by Country USD Million (2023-2028)
  • Table 210. South America Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 211. South America Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 212. South America Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 213. South America Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 214. South America Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 215. Brazil Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 216. Brazil Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 217. Brazil Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 218. Brazil Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 219. Brazil Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 220. Argentina Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 221. Argentina Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 222. Argentina Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 223. Argentina Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 224. Argentina Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 225. Rest of South America Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 226. Rest of South America Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 227. Rest of South America Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 228. Rest of South America Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 229. Rest of South America Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 230. Asia Pacific Cytomegalovirus Infection, by Country USD Million (2023-2028)
  • Table 231. Asia Pacific Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 232. Asia Pacific Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 233. Asia Pacific Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 234. Asia Pacific Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 235. Asia Pacific Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 236. China Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 237. China Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 238. China Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 239. China Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 240. China Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 241. Japan Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 242. Japan Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 243. Japan Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 244. Japan Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 245. Japan Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 246. India Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 247. India Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 248. India Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 249. India Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 250. India Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 251. South Korea Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 252. South Korea Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 253. South Korea Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 254. South Korea Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 255. South Korea Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 256. Taiwan Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 257. Taiwan Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 258. Taiwan Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 259. Taiwan Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 260. Taiwan Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 261. Australia Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 262. Australia Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 263. Australia Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 264. Australia Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 265. Australia Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 266. Rest of Asia-Pacific Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 267. Rest of Asia-Pacific Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 268. Rest of Asia-Pacific Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 269. Rest of Asia-Pacific Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 270. Rest of Asia-Pacific Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 271. Europe Cytomegalovirus Infection, by Country USD Million (2023-2028)
  • Table 272. Europe Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 273. Europe Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 274. Europe Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 275. Europe Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 276. Europe Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 277. Germany Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 278. Germany Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 279. Germany Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 280. Germany Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 281. Germany Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 282. France Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 283. France Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 284. France Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 285. France Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 286. France Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 287. Italy Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 288. Italy Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 289. Italy Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 290. Italy Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 291. Italy Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 292. United Kingdom Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 293. United Kingdom Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 294. United Kingdom Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 295. United Kingdom Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 296. United Kingdom Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 297. Netherlands Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 298. Netherlands Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 299. Netherlands Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 300. Netherlands Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 301. Netherlands Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 302. Rest of Europe Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 303. Rest of Europe Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 304. Rest of Europe Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 305. Rest of Europe Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 306. Rest of Europe Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 307. MEA Cytomegalovirus Infection, by Country USD Million (2023-2028)
  • Table 308. MEA Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 309. MEA Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 310. MEA Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 311. MEA Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 312. MEA Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 313. Middle East Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 314. Middle East Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 315. Middle East Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 316. Middle East Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 317. Middle East Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 318. Africa Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 319. Africa Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 320. Africa Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 321. Africa Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 322. Africa Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 323. North America Cytomegalovirus Infection, by Country USD Million (2023-2028)
  • Table 324. North America Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 325. North America Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 326. North America Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 327. North America Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 328. North America Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 329. United States Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 330. United States Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 331. United States Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 332. United States Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 333. United States Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 334. Canada Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 335. Canada Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 336. Canada Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 337. Canada Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 338. Canada Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 339. Mexico Cytomegalovirus Infection, by Type USD Million (2023-2028)
  • Table 340. Mexico Cytomegalovirus Infection, by Application USD Million (2023-2028)
  • Table 341. Mexico Cytomegalovirus Infection, by Infection USD Million (2023-2028)
  • Table 342. Mexico Cytomegalovirus Infection, by Test type USD Million (2023-2028)
  • Table 343. Mexico Cytomegalovirus Infection, by Drug class USD Million (2023-2028)
  • Table 344. Research Programs/Design for This Report
  • Table 345. Key Data Information from Secondary Sources
  • Table 346. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cytomegalovirus Infection: by Type USD Million (2017-2022)
  • Figure 5. Global Cytomegalovirus Infection: by Application USD Million (2017-2022)
  • Figure 6. Global Cytomegalovirus Infection: by Infection USD Million (2017-2022)
  • Figure 7. Global Cytomegalovirus Infection: by Test type USD Million (2017-2022)
  • Figure 8. Global Cytomegalovirus Infection: by Drug class USD Million (2017-2022)
  • Figure 9. South America Cytomegalovirus Infection Share (%), by Country
  • Figure 10. Asia Pacific Cytomegalovirus Infection Share (%), by Country
  • Figure 11. Europe Cytomegalovirus Infection Share (%), by Country
  • Figure 12. MEA Cytomegalovirus Infection Share (%), by Country
  • Figure 13. North America Cytomegalovirus Infection Share (%), by Country
  • Figure 14. Global Cytomegalovirus Infection share by Players 2022 (%)
  • Figure 15. Global Cytomegalovirus Infection share by Players (Top 3) 2022(%)
  • Figure 16. Global Cytomegalovirus Infection share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2022
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 24. AiCuris Anti-infective Cures GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. AiCuris Anti-infective Cures GmbH (Germany) Revenue: by Geography 2022
  • Figure 26. Vical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Vical, Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Chimerix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Chimerix, Inc. (United States) Revenue: by Geography 2022
  • Figure 30. ViroPharma (United States) Revenue, Net Income and Gross profit
  • Figure 31. ViroPharma (United States) Revenue: by Geography 2022
  • Figure 32. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 34. Clinigen Group Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Clinigen Group Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 36. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 37. CSL Behring (United States) Revenue: by Geography 2022
  • Figure 38. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 40. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 41. Gilead Sciences (United States) Revenue: by Geography 2022
  • Figure 42. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 44. Biotest AG (Germany) Revenue, Net Income and Gross profit
  • Figure 45. Biotest AG (Germany) Revenue: by Geography 2022
  • Figure 46. Shire Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 47. Shire Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 48. Atara Biotherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 49. Atara Biotherapeutics (United States) Revenue: by Geography 2022
  • Figure 50. Helocyte, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 51. Helocyte, Inc. (United States) Revenue: by Geography 2022
  • Figure 52. Global Cytomegalovirus Infection: by Type USD Million (2023-2028)
  • Figure 53. Global Cytomegalovirus Infection: by Application USD Million (2023-2028)
  • Figure 54. Global Cytomegalovirus Infection: by Infection USD Million (2023-2028)
  • Figure 55. Global Cytomegalovirus Infection: by Test type USD Million (2023-2028)
  • Figure 56. Global Cytomegalovirus Infection: by Drug class USD Million (2023-2028)
  • Figure 57. South America Cytomegalovirus Infection Share (%), by Country
  • Figure 58. Asia Pacific Cytomegalovirus Infection Share (%), by Country
  • Figure 59. Europe Cytomegalovirus Infection Share (%), by Country
  • Figure 60. MEA Cytomegalovirus Infection Share (%), by Country
  • Figure 61. North America Cytomegalovirus Infection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • AiCuris Anti-infective Cures GmbH (Germany)
  • Vical, Inc. (United States)
  • Chimerix, Inc. (United States)
  • ViroPharma (United States)
  • Roche Holding AG (Switzerland)
  • Clinigen Group Plc (United Kingdom)
  • CSL Behring (United States)
  • GlaxoSmithKline (United Kingdom)
  • Gilead Sciences (United States)
  • Merck & Co. (United States)
  • Biotest AG (Germany)
  • Shire Pharmaceuticals (United States)
  • Atara Biotherapeutics (United States)
  • Helocyte, Inc. (United States)
Additional players considered in the study are as follows:
Novartis International AG (Switzerland) , Viracyte LLC (United States) , Merck & Co.,Inc.(United States) , Astellas Pharma Global Development Inc. (India) , Chimerix Inc. (United States)
Select User Access Type

Key Highlights of Report


Nov 2023 224 Pages 53 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cytomegalovirus Infection Market Quantitative research analysis
Global Cytomegalovirus Infection Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cytomegalovirus Infection market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AiCuris Anti-infective Cures GmbH (Germany), Vical, Inc. (United States), Chimerix, Inc. (United States), ViroPharma (United States), Roche Holding AG (Switzerland), Clinigen Group Plc (United Kingdom), CSL Behring (United States), GlaxoSmithKline (United Kingdom), Gilead Sciences (United States), Merck & Co. (United States), Biotest AG (Germany), Shire Pharmaceuticals (United States), Atara Biotherapeutics (United States) and Helocyte, Inc. (United States), to name a few.
North America is dominating the Cytomegalovirus Infection Market.
"Vaccine development for CMV infection, where the number of vaccines candidates are still under investigation " is seen as one of the major challenges by many Industry Players of Cytomegalovirus Infection Market
The Cytomegalovirus Infection market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Cytomegalovirus Infection market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Cytomegalovirus Infection Market Report?

Have a Query? Click Here

Other Related Reports

Brain Disease Comprehensive Study by Disease Type (Neurodegenerative Diseases, Neurovascular Diseases, Mental Disorders, Traumatic Brain Injuries), Distribution Channel (Hospitals Pharmacy, Online Ph...
$ 3750
Plasma Fractionation Comprehensive Study by Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), Application (Immunology, Hematology, Neurology, Others), End...
$ 3750
Endometriosis Therapies Comprehensive Study by Type (Hormonal Therapy (Oral Contraceptive Pills, Progestins), Hormone Replacement Therapy (GnRH Agonists, Luteinizing-hormone-releasing hormone recepto...
$ 3750
Thyroid Gland Disorder Treatment Comprehensive Study by Type (Medication, Surgery), Application (Men, Women), Diagnosis (Blood Tests, Imaging Tests, Physical Exams), Disorder Type (Hypothyroidism, Hy...
$ 3450
Lumbar Spine Fusion Comprehensive Study by Type (Anterior lumbar interbody fusion, Lateral lumbar interbody fusion, Posterior lumbar interbody fusion, Others), Application (Hospitals, Ambulatory Surg...
$ 3750
Liver Cirrhosis Comprehensive Study by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis), Application (Hospitals, Specialty Clinics, Others),...
$ 3750